A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies.
OBJECTIVE
Systemic chemotherapy fails to access much of the tumor burden in patients with advanced cancer, significantly limiting its efficacy. In preclinical studies, brief high doses of tyrosine kinase inhibitors (TKI) targeting the human epidermal growth factor receptor (HER) family can prime tumor vasculature for optimal chemotherapeutic delivery and efficacy. This study investigates the clinical relevance of this approach.


METHODS
A phase I clinical study of escalating doses of the HER TKI lapatinib given as a 2-day pulse before a weekly infusion of nab-paclitaxel (100 mg/m(2)) was conducted in patients with advanced solid tumors.


RESULTS
Twenty-five patients were treated. Treatment was associated with grade 1 to 2 toxicities including diarrhea, nausea, rash, neutropenia, neuropathy, fatigue, alopecia, and anemia. The two dose-limiting toxicities were grade 3 vomiting and grade 4 neutropenia, and the maximum tolerated dose of lapatinib was defined as 5250 mg/day in divided doses. Lapatinib concentrations increased with increasing dose. Dynamic Contrast Enhanced Magnetic Resonance Imaging studies in a subset of patients confirmed a decrease in tumor vascular permeability immediately following a lapatinib pulse. Sixty-five percent of evaluable patients experienced a partial or stable response on this therapy, 72% of whom were previously taxane-refractory.


CONCLUSIONS
A 2-day pulse of high-dose lapatinib given before weekly nab-paclitaxel is a feasible and tolerable clinical regimen, suitable for testing this novel vascular-priming chemosensitization hypothesis developed in preclinical models.
Chien
Amy J
AJ
Department of Medicine, University of California San Francisco, San Francisco, California 94143-0875, USA.
Illi
Julie A
JA
Ko
Andrew H
AH
Korn
Wolfgang M
WM
Fong
Lawrence
L
Chen
Lee-may
LM
Kashani-Sabet
Mohammed
M
Ryan
Charles J
CJ
Rosenberg
Jonathan E
JE
Dubey
Sarita
S
Small
Eric J
EJ
Jahan
Thierry M
TM
Hylton
Nola M
NM
Yeh
Benjamin M
BM
Huang
Yong
Y
Koch
Kevin M
KM
Moasser
Mark M
MM
D000284:Administration, Oral; D000068196:Albumin-Bound Paclitaxel; D000418:Albumins / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols; D004305:Dose-Response Relationship, Drug; D066246:ErbB Receptors / Q000378:metabolism*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D000077341:Lapatinib; D008297:Male; D008875:Middle Aged; D053758:Nanoparticles / Q000008:administration & dosage; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D011799:Quinazolines / Q000008:administration & dosage* / Q000009:adverse effects
D000068196:Albumin-Bound Paclitaxel; D000418:Albumins; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077341:Lapatinib; D066246:ErbB Receptors; D017239:Paclitaxel
J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47
9262252
Cancer Chemother Pharmacol. 1999;44(3):241-8
10453726
J Clin Oncol. 2005 May 20;23(15):3502-8
15908660
Cancer Res. 1999 Apr 1;59(7):1454-7
10197613
J Clin Oncol. 2005 Aug 10;23(23):5305-13
15955900
Neoplasia. 2007 Dec;9(12):1066-77
18084614
Science. 2005 Jan 7;307(5706):58-62
15637262
Cancer Res. 1996 May 1;56(9):2112-5
8616858
Pharm Res. 2005 Jun;22(6):867-74
15948030
J Clin Oncol. 2004 Mar 1;22(5):785-94
14990633
Cancer Res. 2006 Feb 15;66(4):2173-80
16489018
Cancer Res. 2004 Jun 1;64(11):3731-6
15172975
Circ Res. 2002 Jun 28;90(12):1243-50
12089061
J Clin Oncol. 2004 Mar 1;22(5):777-84
14990632
Am J Pathol. 2002 Sep;161(3):929-38
12213721
Neoplasia. 2008 May;10(5):489-500
18472966
Cancer Chemother Pharmacol. 2001 Apr;47(4):309-18
11345647
Radiology. 2003 Dec;229(3):885-92
14576446
N Engl J Med. 2006 Dec 14;355(24):2542-50
17167137
J Clin Oncol. 2005 Nov 1;23(31):7785-93
16258082
N Engl J Med. 2007 Dec 27;357(26):2666-76
18160686
Br J Cancer. 1999 Sep;81(2):330-5
10496361
Nature. 2004 Feb 19;427(6976):695
14973470
Rapid Commun Mass Spectrom. 2004;18(3):285-92
14755613
Cancer Chemother Pharmacol. 2007 Mar;59(4):467-75
16896930
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
10655437
Cell Signal. 2008 Oct;20(10):1804-14
18627789
Growth Factors. 2007 Aug;25(4):253-63
18092233
J Clin Oncol. 2008 Jun 20;26(18):3051-6
18565892
Exp Cell Res. 2006 Feb 1;312(3):289-98
16337626
J Magn Reson Imaging. 2007 Dec;26(6):1618-25
17968965
J Clin Oncol. 2008 Jun 20;26(18):2999-3005
18458039